|
A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. Clinical research trials and A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.. A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. clinical trial. Subjects typically recieve the finest healthcare available for their A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.  A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
For Condition: Pancreatic Neoplasms,Metastases, Neoplasm
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Pancreas cancer that cannot be removed by surgery OR that has spread to a new site in your body. - You must have one tumor that can be physically measured or scanned by the doctor. - You have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for pancreas cancer, including 5-FU. - You cannot have any radiation for 4 weeks before starting this study, and you cannot have radiation to the whole pelvis. Exclusion Criteria: - Treatment with any medication or device that has not been approved by regulatory agencies, like the FDA, at the time you enter the study. - Documentation that the cancer has spread to your brain. - Pregnant or breastfeeding. - A second primary cancer. - Unable to stop aspirin or non-steroidal anti-inflammatory agents (like ibuprofen) for 5-8 days.
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 5148;
Study Start Date:
Record last reviewed: March 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035035
Other Pancreatic Neoplasms Studies:
1. High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
2. Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma
3. Evaluation of Bay 59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
4. A Trial of ABI-007 in Patients with Advanced Non-Hematologic Malignancies
5. Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
Related Studies:
Other Pancreatic Neoplasms Clinical Trials
Other Clinical Trials
Other ENSCHEDE Clinical Trials
A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
|
|
|
|
|
|
|
|
